Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00425
|
|||||
| Drug Name |
Cyclophosphamide
|
|||||
| Synonyms |
(+-)-Cyclophosphamide; (-)-Cyclophosphamide; (RS)-Cyclophosphamide; 1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine; 1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin; 4-Hydroxy-cyclophosphan-mamophosphatide; ASTA; ASTA B518; Asta B 518; B 518; B-518; Bis(2-Chloroethyl)phosphami de cyclic propanolamide; Bis(2-Chloroethyl)phosphamide cyclic propanolamide ester; Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester; C 0768; CB 4564; CB-4564; Ciclofosfamida; Ciclofosfamida [INN-Spanish]; Ciclophosphamide; Ciclophosphamide [INN]; Clafen; Claphene; Cycloblastin; Cyclophosphamid; Cyclophosphamide (INN); Cyclophosphamide (TN); Cyclophosphamide (anhydrous form); Cyclophosphamide (anhydrous); Cyclophosphamide Sterile; Cyclophosphamide anhydrous; Cyclophosphamide, (+-)-Isomer; Cyclophosphamides; Cyclophosphamidum; Cyclophosphamidum [INN-Latin]; Cyclophosphan; Cyclophosphane; Cyclophosphanum; Cyclophosphoramide; Cyclostin; Cyklofosfamid; Cyklofosfamid [Czech]; Cytophosphan; Cytophosphane; Cytoxan; Cytoxan (TN); Cytoxan Lyoph; D,L-Cyclophosphamide; Endoxan; Endoxan (TN); Endoxan R; Endoxan-Asta; Endoxana; Endoxanal; Endoxane; Enduxan; Genoxal; Lyophilized Cytoxan; Mitoxan; N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide; Neosar; Neosar (TN); Occupation, cyclophosphamide exposure; Procytox; Procytox (TN); Revimmune; Revimmune (TN); SK 20501; Semdoxan; Sendoxan; Senduxan; Zyklophosphamid; Zyklophosphamid [German]
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Lymphomas [ICD11: 2B33.5] | Approved | [1] | |||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C7H15Cl2N2O2P
|
|||||
| Canonical SMILES |
C1CNP(=O)(OC1)N(CCCl)CCCl
|
|||||
| InChI |
InChI=1S/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12)
|
|||||
| InChIKey |
CMSMOCZEIVJLDB-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 6055-19-2
|
|||||
| Pharmaceutical Properties | Molecular Weight | 261.079 | Topological Polar Surface Area | 41.6 | ||
| Heavy Atom Count | 14 | Rotatable Bond Count | 5 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
0.6
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10090
, 10524283
, 11110909
, 11335421
, 11360660
, 11363752
, 11366314
, 11368876
, 11371419
, 11374027
, 11377038
, 11406490
, 11461632
, 11484807
, 11488962
, 11490186
, 11492119
, 11494672
, 11533313
, 141705
, 141706
, 14848034
, 17404801
, 25765844
, 29222060
, 46505441
, 47365072
, 47440141
, 47515205
, 48334372
, 48413505
, 48415829
, 48423195
, 49855451
, 50000789
, 50105634
, 50105635
, 5080187
, 51092052
, 53777344
, 53788477
, 56310899
, 56311422
, 56313326
, 56313987
, 57288588
, 598053
, 7979009
, 8151862
, 87150
|
|||||
| ChEBI ID |
ChEBI:4027
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | MRP4 | Transporter Info | Multidrug resistance-associated protein 4 | Substrate | [2] | |
| References | ||||||
| 1 | Cyclophosphamide was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Interaction of oxazaphosphorines with multidrug resistance-associated protein 4 (MRP4). AAPS J. 2010 Sep;12(3):300-8. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.